Parkinson's disease and sleep: from biomarkers to clinical stratification

Kimberly Boschi de Abreu Cavalli, Fernando Filippini and Pablo Cortadi
Additional contact information
Kimberly Boschi de Abreu Cavalli: Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Rosario, Argentina
Fernando Filippini: Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Rosario, Argentina
Pablo Cortadi: Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Rosario, Argentina

International Journal of Neurology, 2025, vol. 59, 237

Abstract: Introduction: The study described Parkinson's disease (PD) as a multisystemic neurodegenerative process whose diagnosis had shifted from a clinical approach to one supported by biomarkers and imaging. It noted that nigrostriatal dopaminergic degeneration, α-synuclein aggregation and propagation, and neuroinflammation explained the TRAP motor phenotype and a broad spectrum of non-motor symptoms. It emphasized that sleep disorders (SD), especially REM sleep behavior disorder (RSBD) and hyposmia, acted as early markers with prodromal relevance.Development: The study integrated evidence from pathophysiology, diagnosis, and clinical manifestations. It showed that, in the early stages, dopaminergic involvement manifested as an asymmetric striatal pattern (greater damage in the posterior putamen and relative preservation of the caudate). It documented that SDs—insomnia, obstructive sleep apnea, excessive daytime sleepiness, restless legs syndrome, and RSDS—achieved high prevalences and were associated with cognitive impairment, falls, and poorer quality of life. He noted that polysomnography provided objective confirmation of RLS, OSA, and periodic leg movements, while standardized scales facilitated screening and follow-up when resources were limited.He also highlighted the contribution of psychiatric and autonomic comorbidities (nocturia, bladder dysfunction) and the impact of drugs on sleep architecture.Conclusions: The study concluded that systematically incorporating the screening for TS and other non-motor symptoms into longitudinal neurological assessment enabled early detection, risk stratification, and individualized treatment. It proposed a multidisciplinary approach combining dopaminergic optimization, specific sleep interventions, management of comorbidities, and caregiver education. Finally, it prioritized the validation of multimodal biomarkers and the exploration of modifying therapies targeting neuroinflammation and proteostasis to intervene earlier and more effectively on the course of PD.

Keywords: Parkinson's disease; sleep disorders; TCSR; biomarkers; neuroinflammation (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ijneurology.org/index.php/ijn/article/view/237 Abstract page (text/html)
https://ijneurology.org/index.php/ijn/article/download/237/102 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cwh:ijneur:v:59:y:2025:id:237

DOI: 10.62486/ijn2025237

Access Statistics for this article

More articles in International Journal of Neurology from International Journal of Neurology
Bibliographic data for series maintained by Dr. Andrew Alberto López Sánchez ().